Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647 1654
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17998763 | COMPOSITIONS COMPRISING TROPOELASTIN CROSSLINKED TO HYALURONIC ACID AND THE METHODS OF USE THEREOF | Final Rejection | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
| 18127284 | COMPOSITIONS AND METHODS FOR PRODUCING AND USING ILCS TO TREAT HEALTH CONDITIONS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18004801 | USE OF GDF11 TO DIAGNOSE AND TREAT ANXIETY AND DEPRESSION | Non-Final OA | MCMASTER UNIVERSITY |
| 18322395 | PURIFICATION OF ANTIBODY DRUG CONJUGATES USING A SODIUM PHOSPHATE GRADIENT | Non-Final OA | PFIZER INC. |
| 18010526 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | Final Rejection | STEALTH BIOTHERAPEUTICS INC. |
| 18249287 | ARRAYED PEPTIDE NEOEPITOPE GENERATOR | Non-Final OA | NANTBIO, INC. |
| 18420382 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER | Non-Final OA | CREATE Medicines, Inc. |
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | Non-Final OA | Sorrento Therapeutics, Inc. |
| 18253981 | BROADLY NEUTRALIZING ANTIBODIES TO TICK-BORNE ENCEPHALITIS AND RELATED VIRUSES | Non-Final OA | The Rockefeller University |
| 18265150 | ANTI-CD22 NANO ANTIBODY AND USE THEREOF | Non-Final OA | SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. |
| 17906173 | TARGETED DELIVERY OF EXTRACELLULAR VESICLES | Final Rejection | Evox Therapeutics Ltd. |
| 18301947 | PROCESSES FOR MAKING AND USING A MESENCHYMAL STEM CELL DERIVED SECRETOME | Final Rejection | Combangio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy